Skip to main content
SpringerLink
Log in

Prolactinomas

  • Chapter
Diagnosis and Management of Pituitary Tumors

  • 226 Accesses

Abstract

Prolactinomas are the most commonly occurring pituitary adenomas, accounting for 40–60% of clinically recognizable hyperfunctioning pituitary tumors. Our understanding of their pathogenesis, presentations, and therapy is continually evolving. Prolactinomas pose significant challenges to the diagnostic and therapeutic acumen of the physician. The diagnostic process is taxing, because the clinical presentations, and the laboratory and radiologic features, are varied and nonspecific. Although an optimal therapeutic option is not universally accepted or applied at present, there are available to the physician effective pharmacologic, surgical, and radiotherapeutic ablative treatment options. The choice of the appropriate therapeutic option for a given patient demands considerable therapeutic and considerable skills. The purpose of this chapter is to bring to the clinician up-to-date information that is relevant to meeting these diagnostic and therapeutic challenges.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Horvath E, Kovacs K. The adenohypophysis. In Kovacs K, Asa SL, eds. Functional Endocrine Pathology. Blackwell Scientific, Boston, 1991, p. 245.

    Google Scholar 

  2. Gonzalez JG, Elizondo G, Saldivar D, et al. Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance images. Am J Med 1988;85:217–220.

    PubMed  CAS  Google Scholar 

  3. Molitch ME, Russell EJ. The pituitary “incidentaloma.” Ann Intern Med 1990;112:925–931.

    PubMed  CAS  Google Scholar 

  4. Scheithauer BW. Surgical pathology of the pituitary: the adenomas. Pathol Annu 1980;19:317–374.

    Google Scholar 

  5. Molitch ME. Prolactinoma. In: Melmed S, ed. The Pituitary. Blackwell Science, Cambridge, MA, 1995, p. 443–477.

    Google Scholar 

  6. Selman WR, Laws ER, Scheithauer BW, et al. The occurrence of dural invasion in pituitary adenomas. J Neurosurg 1986;64: 402–407.

    PubMed  CAS  Google Scholar 

  7. Bills DC, Meyer FB, Laws ER Jr, et al. A retrospective analysis of pituitary apoplexy. Neurosurgery 1993;33:602–608.

    PubMed  CAS  Google Scholar 

  8. Guay AT, Freeman R, Rish BL, et al. Calcified pituitary tumor with hyperprolactinemia: selective removal by transphenoidal adenomectomy. Fertil Steril 1978;29:585–588.

    PubMed  CAS  Google Scholar 

  9. Mukada K, Ohta M, Uozumi, et al. Ossified prolactinoma: case report. Neurosurgery 1987;20:473–475.

    PubMed  CAS  Google Scholar 

  10. Horvath E, Kovacs K, Singer W, et al. Acidophil stem cell adenoma of the human pituitary: clinicopathologic analysis of 15 cases. Cancer 1981;47:761–771.

    PubMed  CAS  Google Scholar 

  11. Corenblum B, Sirek AMT, Horvath E, et al. Human mixed soma-totrophic and lactotrophic pituitary adenomas. J Clin Endocrinol Metab 1976;42:857–863.

    PubMed  CAS  Google Scholar 

  12. Lloyd RV, Gikas PW, Chandler WF. Prolactin and growth hormone-producing adenomas. Am J Surg Pathol 1983;7:251–260.

    PubMed  CAS  Google Scholar 

  13. Melmed S, Braunstein GD, Chang RJ, et al. Pituitary tumors secreting growth hormone and prolactin. Ann Int Med 1986; 105: 238–253.

    PubMed  CAS  Google Scholar 

  14. Yamaji T, Ishibashi M, Teramoto A, et al. Hyperprolactinemia in Cushing’ s disease and Nelson’s syndrome. J Clin Endocrinol Metab 1984;58:790–795.

    PubMed  CAS  Google Scholar 

  15. Duello TM, Halmi NS. Pituitary adenoma producing thyrotropin and prolactin. Virchows Arch Pathol Anat Histol 1977;376: 255–265.

    CAS  Google Scholar 

  16. Cunningham GR, Huskins C. An FSH and prolactin-secreting pituitary tumor: pituitary dynamics and testicular histology. J Clin Endocrinol Metab 1977;44:248–253.

    PubMed  CAS  Google Scholar 

  17. Spertini F, Deruaz JP, Perentes E, et al. Luteinizing hormone (LH) and prolactin-releasing pituitary tumor: possible malignant transformation of the LH cell line. J Clin Endocrinol Metab 1986;62: 849–854.

    PubMed  CAS  Google Scholar 

  18. Scheithauer BW, Randall RV, Laws ER Jr, et al. Prolactin cell carcinoma of the pituitary. Cancer 1985;55:598–604.

    PubMed  CAS  Google Scholar 

  19. Molitch ME. Pathogenesis of pituitary tumors. Endocrinol Metab Clin North Am 1987;16:503–527.

    PubMed  CAS  Google Scholar 

  20. Herman V, Fagin J, Gonsky R, et al. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 1990;71:1427–1433.

    PubMed  CAS  Google Scholar 

  21. Jacoby LB, Hedley-Whyte ET, Pulaaski K, et al. Clonal origin in pituitary adenomas. J Neurosurg 1990;73:731–735.

    PubMed  CAS  Google Scholar 

  22. Pichon MF, Bresson D, Peillon F, et al. Estrogen receptors in human pituitary adenomas. J Clin Endocrinol Metab 1980;51:897–902.

    PubMed  CAS  Google Scholar 

  23. Rigg LA, Lein A, Yen SS. Pattern of increase in circulating prolactin levels during human gestation. Am J Obstet Gynecol 1977; 129:454–456.

    PubMed  CAS  Google Scholar 

  24. Molitch ME. Manifestations, epidemiology and pathogenesis of prolactinomas in women. In: Olefsky JM, Robbins RJ, eds. Prolactinomas. Churchill Livingstone, New York, 1986, p. 78.

    Google Scholar 

  25. Wingrave SJ, Kay CR, Vessey MP. Oral contraceptives and pituitary adenomas. Br Med J 1980;1:685–686.

    Google Scholar 

  26. Corenblum B, Donovan L. The safety of physiological estrogen plus progestin replacement therapy with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 1993;59:671–673.

    PubMed  CAS  Google Scholar 

  27. Abboud CF. Hyperprolactinemia and galactorrhoea. In: Samiy AH, Gordon Douglas R Jr, Barondess JA, eds. Textbook of Diagnostic Medicine. Lea & Febiger, Philadelphia, Samiy AH, Gordon Douglas R Jr, Barondess JA (eds). 1987, p. 362–366.

    Google Scholar 

  28. Abboud CF, Laws ER Jr. Diagnosis of pituitary tumors. Endocrinol Metab Clin North Am 1988;17:241–280.

    PubMed  CAS  Google Scholar 

  29. Jacobs HS, Franks S, Murray MA, et al. Clinical and endocrine features of hyperprolactinemic amenorrhoea. Clin Endocrinol 1976;5:437–454.

    Google Scholar 

  30. Molitch ME, Reichlin S. The amenorrhoea, galactorrhoea and hyperprolactinemic syndromes. In: Stollerman GD, ed. Advances in Internal Medicine, vol 26. Year Book Medical, Chicago, 1980, pp. 37–65.

    Google Scholar 

  31. Schlecte J, Sherman B, Halmi N, et al. Prolactin-secreting pituitary tumors in amenorrhoeic women; a comprehensive study. Endocrinol Rev 1986;1:295–308.

    Google Scholar 

  32. von Werder K, Muller OA, Fink U, Jurgen Graf K. Diagnosis and treatment of hyperprolactinemia. In: Imura H, ed. The Pituitary Gland, Raven, New York, 1994, pp. 453–489.

    Google Scholar 

  33. Bergh T, Nilius SJ, Wide L. Hyperprolactinemia in amenorrhoea-incidence and clinical significance. Acta Endocrinol 1977;86: 683–694.

    PubMed  CAS  Google Scholar 

  34. Franks S Murray MAF, Jequier AM, et al. Incidence and significance of hyperprolactinemia in women with amenorrhoea. Clin Endocrinol 1975;4:597–607.

    CAS  Google Scholar 

  35. Klibanski A, Neer RM, Beitins IZ, et al. Decreased bone density in hyperprolactinemic women. N Engl J Med 1980;303:1511–1514.

    PubMed  CAS  Google Scholar 

  36. Greenspan SL, et al. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Int Med 1986;104:777–782.

    PubMed  CAS  Google Scholar 

  37. Klibanski A, Biller BMK, Rosenthal DI, et al. Effects of prolactin and estrogen deficiency in amenorrhoeic bone loss. J Clin Endocrinol Metab 1988;67:124–130.

    PubMed  CAS  Google Scholar 

  38. Schlechte J, Walkner L, Kathol M. A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. J Clin Endocrinol Metab 1992;75:698–703.

    PubMed  CAS  Google Scholar 

  39. Biller BM, Baum HB, Rosenthal DI, et al. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhoea. J Clin Endocrinol Metab 1992;75:692–697.

    PubMed  CAS  Google Scholar 

  40. Klibanski A, Greenspan SL. Increased bone mass in treated hyperprolactinemic amenorrhoeic women. NEJM 1986;315: 542–546.

    PubMed  CAS  Google Scholar 

  41. Glickman SP, Rosenfeld RL, Bergenstal RM, et al. Multiple androgenic abnormalities, including elevated free testosterone, in hyperprolactinemic women. J Clin Endocrinol Metab 1982;55:251–257.

    PubMed  CAS  Google Scholar 

  42. Corenblum B, Taylor PJ. The hyperprolactinemic polycystic ovarian syndrome may not be a distinct entity. Fertil Steril 1982;38:549–552.

    PubMed  CAS  Google Scholar 

  43. Futterweit W, Krieger DT. Pituitary tumors associated with hyperprolactinemia and polycystic ovrian disease. Fertil Steril 1979;31:608–613.

    PubMed  CAS  Google Scholar 

  44. Berezin M, Shimon I, Hadani M. Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma). J Endocrinol Invest 1995;18:436–441.

    PubMed  CAS  Google Scholar 

  45. Carter JN, Tyson JE, Tolis G, et al. Prolactin-secreting tumors and hypogonadism in 22 men. N Engl J Med 1978;299:847–852.

    PubMed  CAS  Google Scholar 

  46. Grisoli F, Vincentelli F, Jacquet P, et al. Prolactin-secreting adenoma in 22 men. Surg Neurol 1980;13:241–247.

    PubMed  CAS  Google Scholar 

  47. Mindermann T, Wilson CB. Pituitary adenomas in childhood and adolescence [Review]. J Pediatr Endocrinol Metab 1995;8:79–83.

    PubMed  CAS  Google Scholar 

  48. Partington M, Davis D, Laws E, et al. Pituitary adenomas in childhood and adolescence. J Neurosurg 1994;80:209–216.

    PubMed  CAS  Google Scholar 

  49. Burgess JR, Shepherd JJ, Parameswaran V, et al. Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN I): clinical, biochemical and radiologic features of pituitary disease in a large MEN I kindred. J Clin Endocrin Metab 1996;81:2642–2646.

    CAS  Google Scholar 

  50. Scheithauer BW, Laws ER Jr, Kovacs K, et al. Pituitary adenomas of the multiple endocrine neoplasia type I syndrome. Semin Diagn Pathol 1987;4:205–211.

    PubMed  CAS  Google Scholar 

  51. Abboud CF. Anterior pituitary failure. In: Melmed S, ed. The Pituitary. Blackwell Science, Cambridge, MA, 1995, p. 341.

    Google Scholar 

  52. Thomas JE, Yoss RE. The parasellar syndrome: problems in determining etiology. Mayo Clin Proc 1970;45:617–623.

    PubMed  CAS  Google Scholar 

  53. Molitch ME. Evaluation and treatment of the patient with a pituitary incidentaloma. J Clin Endocrinol Metab 1995;80:3–6.

    PubMed  CAS  Google Scholar 

  54. Molitch ME. Prolactin. In Melmed S (ed). The Pituitary. Blackwell Science, Cambridge, MA, 1995, pp. 136–186.

    Google Scholar 

  55. Franks S, Jacobs HS, Nabarro JDN. Prolactin concentrations in patients with acromegaly-clinical significance and response to surgery. Clin Endocrinol 1976;5:63–69.

    CAS  Google Scholar 

  56. Bevan JS, Burke CW, Esiri MM, et al. Misinterpretation of prolactin levels leading to management errors in patients with sellar enlargement. Am J Med 1987;82:29–32.

    PubMed  CAS  Google Scholar 

  57. Gharib H, Frey HM, Laws ER Jr, et al. 1983. Coexistent primary empty sella syndrome and hyperprolactinemia. Arch Intern Med 1983, p. 143.

    Google Scholar 

  58. Josse R. Autoimmune hypophysitis. In: Volpe R ed. Autoimmune Diseases of the Endocrine System. CRC, Boca Raton, FL, 1990, p. 331.

    Google Scholar 

  59. Freda PU, Wardlaw SL, Post KD, et al. Incidence and significance of hyperprolactinemia in women with amenorrhea. Clin Endocrinol 1975;4:597–607.

    Google Scholar 

  60. Kapcala LP, Molitsch ME, Post KD, et al. Galactorrhoea, oligo/ amenorrhoea, and hyperprolactinemia in patients with craniopharyngioma. J Clin Endocrinol Metab 1980;51:798–800.

    PubMed  CAS  Google Scholar 

  61. Munt PW, Marshall RN, Underwood LE. Hyperprolactinemia in sarcoidosis. Incidence and utility in predicting hypothalamic involvement. Ann Rev Respir Dis 1975;112:269–272.

    CAS  Google Scholar 

  62. Tabarin A, Corcuff JB, Dautheribes M, et al. Histiocytosis X of the hypothalamus. J Endocrinol Invest 1991;14:139–145.

    PubMed  CAS  Google Scholar 

  63. Tang LCH, Ma H. Hyperprolactinemic amenorrhoea after external irradiation for nasopharyngeal carcinoma. Fertil Steril 1983; 40:118–119.

    PubMed  CAS  Google Scholar 

  64. Carson HE. Drugs and pituitary function. In: Melmed S, ed. The Pituitary. Blackwell Science, Boston, 1995, pp. 645–660.

    Google Scholar 

  65. Edwards CRW, Forsyth IA, Besser GM. Amenorrhoea, galactorrhoea and primary hypothyroidism with high circulating levels of prolactin. Br Med J 1971;3:462–464.

    PubMed  CAS  Google Scholar 

  66. Honbo KS, Herle AJV, Kellett KA. Serum prolactin levels in untreated primary hypothyroidism. Am J Med 1978;64:782–787.

    PubMed  CAS  Google Scholar 

  67. Smallridge RC. Thyrotropin-secreting pituitary tumors. Endocrinol Metab Clin North Am 1987;16:765–792.

    PubMed  CAS  Google Scholar 

  68. Morley JE, Dawson M., Hodgkinson H, et al. Galactorrhoea and hyperprolactinemia associated with chest wall injury. J Clin Endocrinol Metab 1977;45:931–935.

    PubMed  CAS  Google Scholar 

  69. Herman VS, Kalk WJ. Neurogenic prolactin release: effects of mastectomy and thoracotomy. Prog Reprod Biol 1980;6:83.

    Google Scholar 

  70. Borzio M, Caldara R, Ferrari C. Growth hormone and prolactin secretion in liver cirrhosis; evidence for dopaminergic dysfunction. Acta Endocrinol 1981;97:441–447.

    PubMed  CAS  Google Scholar 

  71. Cowden EA, et al. Hyperprolactinemia in renal disease Clin Endocrinol 1978;9:241–248.

    CAS  Google Scholar 

  72. Hou SH, Grossman S, Molitch ME. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am J Kidney Dis 1985;6:245–249.

    PubMed  CAS  Google Scholar 

  73. Lim VS, Kathpalia S, Frohman LA. Hyperprolactinemia and impaired pituitary responses to suppression and stimulation in chronic renal failure. Reversal following transplantation. J Clin Endocrinol Metab 1979;48:101–107.

    PubMed  CAS  Google Scholar 

  74. Morgan MY, Jacobovitz AW, Gore MB, et al. Serum prolactin in liver disease and its relationship to gynecomastia. Gut 1978; 19: 170–174.

    PubMed  CAS  Google Scholar 

  75. Stanisic TH, Donova J. Prolactin secreting renal cell carcinoma. J Urol 1986;136:85–86.

    PubMed  CAS  Google Scholar 

  76. Hoffman WH, Gala RR, Kovacs K, et al. Ectopic prolactin secretion from a gonadoblastoma. Cancer 1987;60:2690–2695.

    PubMed  CAS  Google Scholar 

  77. Kallenberg GA, Pesce CM, Norman B, et al. Ectopic hyperprolactinemia resulting from an ovarian teratoma. JAMA 1990;263: 2472–2474.

    PubMed  CAS  Google Scholar 

  78. Nabarro JD. Pituitary prolactinomas. Clin Endocrinol 1982; 17: 129–155.

    CAS  Google Scholar 

  79. Randall RV, Laws ER Jr, Abboud CF, et al. Transphenoidal microsurgical treatment of prolactin-producing pituitary adenomas. Mayo Clin Proc 1983;58:108–121.

    PubMed  CAS  Google Scholar 

  80. Klijn JGM, Lamberts SWJ, DeJong FH, et al. The importance of pituitary tumor size in patients with hyperprolactinemia in relation to hormonal variables and extrasellar extension of tumor. Clin Endocrinol 1980;12:341–355.

    CAS  Google Scholar 

  81. Molitch ME, Reichlin S. Neuroendocrine studies of prolactin secretion in hyperprolactinemic states. In: Mena F, Valverde-Rodriguez C, eds. Prolactin Secretion: A Multidisciplinary Approach. Academic, New York, 1984, p. 393.

    Google Scholar 

  82. Oehler M, Chakeres D. Diagnostic imaging of the sellar region. In: Becker KL, ed. Principles and Practice of Endocrinology and Metabolism. 2nd ed. Lippincott JB, Philadelphia, 1995, pp. 207–223.

    Google Scholar 

  83. Martin TL, Kim M, Malarkey WB. The natural history of idiopathic hyperprolactinemia. J Clin Endocrinol Metab 1985;60:855–858.

    PubMed  CAS  Google Scholar 

  84. March DM, Kletzky OA, Davajan V, et al. Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 1981;139:835–844.

    PubMed  CAS  Google Scholar 

  85. Schlecte J, Dolan K, Sherman B, et al. The natural history of untreated hyperprolactinemia: A prospective analysis. J Clin Endocrinol Metab 1989;68:412–418.

    Google Scholar 

  86. Sisam D A, Sheehan JP, Sheeler LR. The natural history of untreated microprolactinoma. Fertil Steril 1987;48:67–71.

    PubMed  CAS  Google Scholar 

  87. Weiss MH, Teal J, Gott P, et al. Natural history of microprolactinomas: six-year follow-up. Neurosurgery 1983;12:180–183.

    PubMed  CAS  Google Scholar 

  88. Jacquet P. Medical therapy of prolactinomas. Acta Endocrinol 1993;129(Sl):31–33.

    Google Scholar 

  89. Sibley DR, Creese I. Interactions of ergot alkaloids with anterior pituitary D-2 dopamine receptors. Mol Pharmacol 1983;23: 585–593.

    PubMed  CAS  Google Scholar 

  90. Thorner MO, Fluckiger E, Calne DB. Bromocriptine: A Clinical and Pharmacological Review. Raven, New York, 1980.

    Google Scholar 

  91. Vance ML, Evans WS, Thorner MO. Bromocriptine. Ann Intern Med 1984;100:78–91.

    PubMed  CAS  Google Scholar 

  92. Bouloux PMJ, Besser GM, Grossman A. Clinical evaluation of lysuride in the management of hyperprolactinemia. Br Med J 1987;294:1323–1324.

    CAS  Google Scholar 

  93. Chidini P, Liuzzi A, Cozzi R, et al. Size reduction of macro-prolactinoma by bromocriptine or lisuride treatment. J Clin Endocrinol Metab 1981;53:737–743.

    Google Scholar 

  94. Ciccarelli E, Camanni F. Diagnosis and drug therapy of prolactinoma. Drugs 1996;51(6):954–965.

    PubMed  CAS  Google Scholar 

  95. Schran HR, Bhuta SI, Schwarz HJ, et al. The pharmacokinetics of bromocriptine in man. In: Goldstein M, Calne D, Lieberman A, Thorner M, eds. Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatric Aspects. Raven, New York, 1980, pp. 125–139.

    Google Scholar 

  96. Tindall GT, Kovacs L, Horvath E, et al. Human prolactin- producing adenomas and bromocriptine; a histologic, immunocytochemi-cal, ultrastructural and morphometric study. J Clin Endocrinol Metab 1982;55:1178–1183.

    PubMed  CAS  Google Scholar 

  97. Bevan JS, Webster J, Burke CW, et al. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992;13:220–240.

    PubMed  CAS  Google Scholar 

  98. Bonneville JF, Poulignot D, Cattin F et al. Computed tomographic demonstration of the effects of bromocriptine on pituitary microadenoma size. Radiology 1982;143:451–455.

    PubMed  CAS  Google Scholar 

  99. Pelligrini I, Rasolonjanahary R, Gunz G, et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989; 69:500–509.

    Google Scholar 

  100. McGregor AM, et al. Effects of bromocriptine on pituitary tumor size. Br Med J 1979;2:700–703.

    PubMed  CAS  Google Scholar 

  101. Corenblum B, Taylor PJ. Long term follow-up of hyperprolactinemic women treated with bromocriptine. Fertil Steril 1983;40:596–599.

    PubMed  CAS  Google Scholar 

  102. Johnston DG, Prescott RWG, Kendall-Taylor P, et al. Hyper-prolactinemia: long term effects of bromocriptine. Am J Med 1983;75:868–874.

    PubMed  CAS  Google Scholar 

  103. McElvaney NG, Wilcox PG, Churg A, et al. Pleuropulmonary disease during bromocriptine treatment of Parkinson’s disease. Arch Intern Med 1988;148:2231–2236.

    PubMed  CAS  Google Scholar 

  104. Bowler JV, Ormerod IE, Legg NJ. Retroperitoneal fibrosis and bromocriptine. Lancet 1986, ii:466.

    Google Scholar 

  105. Davis JRE, Sheppard MC, Heath D A. Giant invasive prolactinoma. Q J Med 1990;74:227–238.

    PubMed  CAS  Google Scholar 

  106. Kok JG, Bartelink AKM, Schulte BPM, et al. Cerebrospinal fluid rhinorrhoea during treatment with bromocriptine for prolactinoma. Neurology 1985;35:1193–1195.

    PubMed  CAS  Google Scholar 

  107. Boulanger CM, Mashechak CA, Chang RJ. Lack of tumor reduction in hyperprolactinemic women with extrasellar macroadenomas treated with bromocriptine. Fertil Steril 1985;44:532–535.

    PubMed  CAS  Google Scholar 

  108. Dallabonzana D, Spella B, Oppizzi G, et al. Reenlargement of macroprolactinomas during bromocriptine treatment: report of two cases. J Endocrinol Invest 1983;6:47–50.

    PubMed  CAS  Google Scholar 

  109. Katz E, Schran HF, Adashi EY. Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate: a novel approach to intolerance of oral therapy Obstet Gynecol 1989;73:517–520.

    PubMed  CAS  Google Scholar 

  110. Espinos JJ, Rodriquez-Espinosa J, Webb SM, et al. Long-acting repeatable bromocriptine in the treatment of patients with micro-prolactinoma intolerant or resistant to oral dopaminergics. Fertil Steril 1994;62:926–931.

    PubMed  CAS  Google Scholar 

  111. Haase R, Jaspers C, Schulte HM, et al. Control of prolactin-secreting macroadenomas with parenteral, longacting bromocriptine in 30 patients treated for up to 3 years. Clin Endocrinol 1993;38:165–176.

    CAS  Google Scholar 

  112. Colao A, Merola B, Sarnacchiaro F, et al. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas. Horm Res 1995;44:222–228.

    PubMed  CAS  Google Scholar 

  113. Ferrari C, Parrachi A, Mattei AM, et al. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol 1992;126:489–494.

    PubMed  CAS  Google Scholar 

  114. Webster J, Piscetelli G, Polli A, et al. Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinemia: a placebo-controlled, double-blind, multicenter study. Clin Endocrinol 1992;37:534–541.

    CAS  Google Scholar 

  115. Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenor-rhoea. N Engl J Med 1994;331:904–909.

    PubMed  CAS  Google Scholar 

  116. Ciccarelli E, Giusti M, Miola C, et al. Effectiveness and tolerability of long term treatment with cabergoline: a new long-lasting ergoline derivative, in hyperprolactinemic women. J Clin Endocrinol Metab 1989;69:725–728.

    PubMed  CAS  Google Scholar 

  117. Brue T. Pelligrini Lancet. Gunz G, et al. Effects of the dopamine agonist CV205–502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab 1992;74:577–584.

    PubMed  CAS  Google Scholar 

  118. Serri O, Beauregard H, Lesage J, et al. Long-term treatment with CV 205–502 in patients with prolactin- secreting pituitary macroadenomas. J Clin Endocrinol Metab 1990;71:682–687.

    PubMed  CAS  Google Scholar 

  119. Vance ML, Lipper M, Klibanski A, et al. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV205–502. Ann Int Med 1990;112:668–673.

    PubMed  CAS  Google Scholar 

  120. Van-der-Lely AJ, Brownell J, Lamberts SW. The efficacy and tolerability of CV205–502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant of bromocriptine. J Clin Endocrinol Metab 1991;72:1136–1141.

    PubMed  CAS  Google Scholar 

  121. Klezky OA, Borenstein R, Mileilkowsky GN. Pergolide and bromocriptine for the treatment of patients with hyperprolactinemia. Am J Obstet Gynecol 1986;15:431–435.

    Google Scholar 

  122. Lambert SWJ, Quick RFP. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia. J Clin Endocrinol Metab 1991;72:635–641.

    Google Scholar 

  123. Radwanska E, McGarrigle HHG, Little V, et al. Induction of ovulation in women with hyperprolactinemic amenorrhoea using clo-miphene and human chorionic gonadotropin or bromocriptine. Fertil Steril 1979;32:187–192.

    PubMed  CAS  Google Scholar 

  124. Bergh T, Skarin G, Nilius SJ, et al. Pulsatile GnRH therapy—an alternative successful therapy for induction of ovulation in infertile normo- and hyperprolactinemic amenorrhoeic women with pituitary tumors. Acta Endocrinol 1985;110:440–444.

    PubMed  CAS  Google Scholar 

  125. Poison DW, Sagle M, Mason HD, et al. Ovulation and normal luteal function during LHRH treatment of women with hyperprolactinemic amenorrhoea. Clin Endocrinol 1986;24:531–537.

    Google Scholar 

  126. Krupp P, Monka C, Richter K. The safety aspects of infertility treatments. Program of the Second World Congress of Gynecology and Obstetrics, Rio de Janeiro, October 1988:9.

    Google Scholar 

  127. Feigenbaum SL, Downey DE, Wilson CB, et al. Transphenoidal pituitary resection for preoperative diagnosis of a prolactin-secreting pituitary adenoma in women: long term follow-up. J Clin Endocrinol Metab 1996;81:1171–1179.

    Google Scholar 

  128. Laws ER Jr. Pituitary surgery. Endocrinol Metab Clin North Am 1987;16:647–665.

    PubMed  Google Scholar 

  129. Laws ER Jr, Ebersold MJ, Piepgras DG, et al. The role of surgery in the management of prolactinoma. In: Macleod RM, Thorner MO, Scapagnini U, eds. Prolactin, Basic and Clinical Correlates. Springer-Verlag, New York, 1985, p. 849.

    Google Scholar 

  130. Schlecte J A, Sherman BM, Chapler FK, et al. Long-term follow-up of women with surgically-treated prolactin-secreting tumors. J Clin Endocrinol Metab 1986;62:1296–1301.

    Google Scholar 

  131. Soule SG, Farhi J, Conway GS, et al. The outcome of hypophysec-tomy for prolactinomas in the era of dopamine agonist therapy. Clin Endocrinol 1996;44:711–716.

    CAS  Google Scholar 

  132. Thomson JA, Davies DL, McLaren EH, et al. Ten year follow-up of microprolactinoma treated by transphenoidal surgery. Br Med J 1994;309:1409–1416.

    CAS  Google Scholar 

  133. Grossman A, Cohen BL, Charlesworth M, et al. Treatment of prolactinomas with megavoltage radiotherapy. Br Med J 1984;288: 1105–1109.

    CAS  Google Scholar 

  134. Johnston D, Hall K, Kendall-Taylor P, et al. The long-term effects of megavoltage radiotherapy as a sole or combined therapy for large prolactinomas: studies with high-definition computerized tomography. Clin Endocrinol 1986;24:675–685.

    CAS  Google Scholar 

  135. Tran LM, Blount L, Horton D, et al. Radiation therapy of pituitary tumors: results in 95 cases. Am J Clin Oncol 1991;14:25–29.

    PubMed  CAS  Google Scholar 

  136. Zierhut D, Flentje M, Adolph J, et al. External radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys 1995;33: 307–314.

    PubMed  CAS  Google Scholar 

  137. Mehta MP, Rozental JM. Radiotherapy of pituitary-hypothalamic tumors. In: Becker KL, ed. Principles and Practice of Endocrinology and Metabolism, 2nd ed. Lippincott JB, Philadelphia, 1995, pp. 229–238.

    Google Scholar 

  138. Demura R, Kubo O, Demura H, et al. Changes in computed tomographic findings in microprolactinomas before and after bromocriptine. Acta Endocrinol 1985;110:308–312.

    PubMed  CAS  Google Scholar 

  139. Serri O, Rasio E, Beauregard H, et al. Recurrence of hyperprolactinemia after selective transphenoidal adenomectomy in women with prolactinoma. N Engl J Med 1983;309:280–283.

    PubMed  CAS  Google Scholar 

  140. Pelkonen R, Grahne B, Hirvonen E, et al. Pituitary function in prolactinoma. Effect of surgery and postoperative bromocriptine therapy Clin Endocrinol 1981;14:335–348.

    CAS  Google Scholar 

  141. Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: Result of a prospective multicenter study. J Clin Endocrinol Metab 1985;60: 698–705.

    PubMed  CAS  Google Scholar 

  142. Wass J AH, et al. Bromocriptine in the management of large pituitary tumors. Br Med J 1982;284:1908–1911.

    CAS  Google Scholar 

  143. Crosignani PG, Ferrari C, Mattei AM. Visual field defects and reduced visual acuity during pregnancy in two patients with prolactinoma: rapid regression of symptoms under bromocriptine; Case reports. Br J Obstet Gynecol 1984;91:821–823.

    CAS  Google Scholar 

  144. Nissim M, Ambrosi B, Bernasconi V, et al. Bromocriptine treatment of macroprolactinomas: studies on the time course of tumor shrinkage and morphology. J Endocrinol 1982;5:409–415.

    CAS  Google Scholar 

  145. Landolt AM, Osterwalder V. Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J Clin Endocrinol Metab 1984; 58:1179–1183.

    PubMed  CAS  Google Scholar 

  146. Bevan JS, Adams CBT, Burke CW, et al. Factors in the outcome of transphenoidal surgery for prolactinoma and non-functioning pituitary tumor, including pre-operative bromocriptine therapy. Clin Endocrinol 1987;26:541–556.

    CAS  Google Scholar 

  147. Wang C, Lam KSL, Ma JTC, et al. Long-term treatment of hyperprolactinemia with bromocriptine: effect of drug withdrawal. Clin Endocrinol 1987;27:363–371.

    CAS  Google Scholar 

  148. Thorner MO, Perryman RL, Rogol AD, et al. Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J Clin Endocrinol Metab 1981;53:480–483.

    PubMed  CAS  Google Scholar 

  149. Trautman JC, Laws ER. Visual status after transphenoidal surgery at the Mayo Clinic. Am J Ophthalmol 1983;96:200–208.

    Google Scholar 

  150. Nelson AT Jr, Tucker HSG Jr, Becker DP. Residual anterior pituitary function following transphenoidal resection of pituitary macroadenomas. J Neurosurg 1984;61:557–580.

    Google Scholar 

  151. Barrow DL, Tindall GT. Loss of vision after transphenoidal surgery Neurosurgery 1990;27:60–68.

    PubMed  CAS  Google Scholar 

  152. Molitch ME. Pregnancy and the hyperprolactinemic women. N Engl J Med 1985;312:1364–1370.

    PubMed  CAS  Google Scholar 

  153. Ruiz-Velasco V, Tolis G. Pregnancy in hyperprolactinemic women. FertilSteril 1984;41:793–805.

    PubMed  CAS  Google Scholar 

  154. Gemzell C, Wang CF. Outcome of pregnancy in women with pituitary adenoma. Fertil Steril 1979;31:363–372.

    PubMed  CAS  Google Scholar 

  155. Pragor D, Braunstein GD. Pituitary disorders during pregnancy. Endocrinol Metab Clin North Am 1995;24(1): 1–14.

    Google Scholar 

  156. Bergh T, Nilius SJ, Wide L. Clinical course and outcome of pregnancies in amenorrhoeic women with hyperprolactinemia and pituitary tumors. Br Med J 1978;1:875–880.

    PubMed  CAS  Google Scholar 

  157. Turkalj I, Braum P, Krupp P. Surveillance of bromocriptine in pregnancy. JAMA 1982;247:1589–1591.

    PubMed  CAS  Google Scholar 

  158. Brodsky JB, Cohen EN, Brown BW, et al. Surgery during pregnancy and fetal outcome. Am J Obstet Gynecol 1980; 138: 1165–1167.

    PubMed  CAS  Google Scholar 

  159. Laws ER Jr, Fode NC, Randall RV, et al. Pregnancy following transphenoidal resection of prolactin-secreting pituitary tumors. J Neurosurg 1983;58:685–688.

    PubMed  Google Scholar 

  160. Samaan NA, Schultz PN, Leavens TA, et al. Pregnancy after treatment in patients with prolactinoma: operation vs bromocriptine. Am J Obstet Gynecol 1986;155:1300–1305.

    PubMed  CAS  Google Scholar 

  161. Yen SSC, Divers WA Jr. Prolactin-producing microadenomas in pregnancy. Obstet Gynecol 1983;61:425–429.

    Google Scholar 

  162. Konopka P, et al. Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol 1983; 146: 935–938.

    PubMed  CAS  Google Scholar 

  163. Crosignani PG, Mattei AM, Scarduelli C, et al. Is pregnancy the best treatment for hyperprolactinemia. Hum Reprod 1989;4: 910–912.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Charles F. Abboud MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael J. Ebersold MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Neurosurgery, Department of Surgery, University Health Network, University of Toronto, Toronto, Ontario, Canada

    Kamal Thapar MD, PhD

  2. Department of Pathology and Laboratory Medicine, St. Michael’s Hospital, Toronto, Ontario, Canada

    Kalman Kovacs MD, PhD

  3. Department of Pathology, Mayo Clinic, Rochester, MN, USA

    Bernd W. Scheithauer MD  & Ricardo V. Lloyd MD, PhD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Abboud, C.F., Ebersold, M.J. (2001). Prolactinomas. In: Thapar, K., Kovacs, K., Scheithauer, B.W., Lloyd, R.V. (eds) Diagnosis and Management of Pituitary Tumors. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-217-3_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-217-3_16

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9693-2

  • Online ISBN: 978-1-59259-217-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation